# Avalo Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Avalo Therapeutics, Inc.).

## Overview

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on immune dysregulation and inflammatory disease. Its lead program is AVTX-009, an anti-IL-1β monoclonal antibody being developed for hidradenitis suppurativa and potentially other immune-mediated indications. The company is still in the development phase and does not yet have commercial product revenue, so its value is tied primarily to clinical execution, regulatory progress, and business development optionality. Avalo also evaluates opportunities to out-license programs, indications, or geographies as part of its path to value creation.

## Products & services

• AVTX-009 anti-IL-1β monoclonal antibody
• Phase 2 LOTUS trial in hidradenitis suppurativa
• Immune dysregulation and inflammatory disease pipeline
• In-licensing of complementary immune-mediated compounds
• Out-licensing of programs, indications, or geographies

- **Lead clinical asset development** (70%) — Development of AVTX-009 and related clinical-stage work in immune-mediated disease.
- **Clinical trial operations** (20%) — Sponsor-led execution of the LOTUS Phase 2 trial across multiple countries.
- **Business development and licensing** (10%) — Out-licensing, in-licensing, and partnering activities for programs and geographies.

- AVTX-009 anti-IL-1β monoclonal antibody
- Phase 2 LOTUS trial in hidradenitis suppurativa
- Immune dysregulation and inflammatory disease pipeline
- In-licensing of complementary immune-mediated compounds
- Out-licensing of programs, indications, or geographies

## Customers

Avalo does not sell commercial medicines today; its primary counterparties are clinical trial participants, investigators, and trial sites that support AVTX-009 development. In a broader business sense, the company’s future customers would be physicians, hospitals, and patients in immune-mediated disease markets if a product is approved. The company also depends on pharmaceutical partners and licensees that may acquire rights to indications or geographies through out-licensing transactions. Because the business is pre-revenue and development-stage, investor and partner confidence in the clinical data package is central to its ability to attract funding and collaborations.

- **Clinical trial participants** (primary) — Adults with moderate to severe hidradenitis suppurativa enrolled to evaluate AVTX-009 safety and efficacy.
- **Clinical investigators and trial sites** (primary) — Hospitals, clinics, and research centers that execute the LOTUS protocol and generate the data package.
- **Strategic pharmaceutical partners** (secondary) — Companies that may license AVTX-009 rights, fund development, or collaborate on specific indications or regions.
- **Future prescribers and patients** (emerging) — Dermatology and immunology stakeholders who would use the product if it reaches approval and commercialization.

- Clinical trial patients enrolled in the LOTUS study for hidradenitis suppurativa
- Investigators and trial sites running the Phase 2 program
- Potential pharmaceutical partners seeking rights to AVTX-009 or other assets
- Future physicians and patients in immune-mediated inflammatory diseases
- Potential licensees for specific geographies or indications

## Geography

Avalo’s current operating footprint is centered in the United States, where it is headquartered and where a meaningful portion of its clinical and corporate activity is managed. The LOTUS Phase 2 trial is multinational, with sites in North America, Europe, and Australia, which broadens patient access but also increases operational complexity. The company specifically cites trial locations in the United States, Canada, France, Germany, Italy, Spain, Bulgaria, Czech Republic, Greece, Poland, Australia, Turkey, and Slovakia. Because the company is still in development, geography matters mainly through clinical execution, regulatory coordination, and the ability to expand or out-license rights by region.

- **United States** (35%) — Core corporate base and a major trial location.
- **Europe** (50%) — Multinational LOTUS trial footprint across several European countries plus Turkey.
- **Australia** (15%) — Additional clinical trial geography.

- Headquartered in the United States
- Phase 2 LOTUS trial runs across the U.S. and multiple foreign markets
- European trial sites expand patient recruitment and data diversity
- Australia and Turkey add further geographic reach for clinical operations
- Geographic expansion supports future out-licensing by indication or region

## Strategy

Avalo’s near-term strategy is to advance AVTX-009 through the Phase 2 LOTUS trial and prepare for the next stage of development in hidradenitis suppurativa. Management also wants to evaluate indication expansion for AVTX-009, which could broaden the commercial opportunity if the asset shows clinical promise. A second strategic pillar is business development: the company may out-license rights to compounds, indications, or geographies, or pursue strategic alliances and asset sales. Because the company remains pre-commercial, preserving cash runway while creating optionality through clinical milestones is central to its strategy.

- **Advance AVTX-009 through Phase 2 LOTUS** (short-term) — Clinical data is the main value driver for a pre-commercial biotech and determines whether the asset can progress or be partnered.
- **Expand AVTX-009 into additional indications** (medium-term) — A broader label opportunity can increase the asset’s commercial value and improve partnering leverage.
- **Monetize through partnering and out-licensing** (medium-term) — Non-dilutive capital and shared development risk are important for a company with ongoing operating losses.

- Complete the Phase 2 LOTUS trial in hidradenitis suppurativa
- Prepare AVTX-009 for the next stage of clinical development
- Evaluate additional indications for AVTX-009
- Use out-licensing to monetize programs, indications, or geographies
- Pursue partnerships, alliances, or asset sales to extend runway
- Maintain sufficient liquidity through at least the next development milestones

## Risks

Avalo’s biggest risk is clinical development failure, since the company’s value depends heavily on AVTX-009 and the LOTUS trial outcome. As a pre-revenue biotech, it also faces financing risk: if capital markets weaken or partnering terms are unattractive, the company may need to dilute shareholders or give up valuable rights. Regulatory risk is material because even promising data may not translate into FDA or foreign approval, and trial design, endpoint selection, and safety findings can all affect the path forward. More generally, biotech companies face high R&D burn, trial enrollment delays, competitive therapies in inflammatory disease, and uncertainty around whether a single asset can support a durable commercial franchise.

- **Dependence on AVTX-009 and the LOTUS trial** [critical] — The company’s near-term value creation is concentrated in a single lead asset and one key Phase 2 study.
- **Need for future financing and potential dilution** [high] — Avalo has a history of operating and cash losses and may need equity or partnering capital to fund development.
- **Regulatory and approval uncertainty** [high] — Positive clinical results do not guarantee FDA or ex-U.S. approval, and the approval path may require additional studies.
- **Clinical execution and enrollment delays** [medium] — Multinational trials depend on site activation, patient recruitment, and protocol adherence across many countries.
- **Competitive landscape in immune-mediated disease** [medium] — Competing biologics and emerging therapies could reduce the commercial opportunity even if AVTX-009 succeeds.

- Clinical trial failure could eliminate or materially reduce AVTX-009 value
- Financing risk is high because the company has recurring operating losses
- Out-licensing or collaboration terms may require surrendering future economics
- Regulatory approval is uncertain even if Phase 2 data are positive
- Enrollment, site execution, and safety issues can delay development timelines
- Competition in inflammatory disease may limit future commercial positioning

## Accounting

Avalo’s financial statements are shaped by judgment-heavy estimates typical of a clinical-stage biotech. Research and development expense depends heavily on clinical trial accruals, CMC spending, and nonclinical program costs, so timing differences in vendor invoices or milestone recognition can move quarterly results materially. The company also discloses fair value measurements and derivative liabilities, which can create non-cash volatility in other income or expense as assumptions change. Because Avalo has no commercial product revenue today, revenue recognition is not a major operating driver, but any future licensing or collaboration revenue would likely be highly dependent on contract terms and milestone timing. Management also highlights going-concern-style liquidity assessment and stock-based compensation, both of which are important for understanding cash burn and reported losses.

- **Clinical trial accruals** — Can shift reported operating loss between periods
- **Fair value of derivative liabilities** — Can materially distort net income or loss
- **Stock-based compensation** — Raises reported expenses without immediate cash outflow
- **Revenue recognition for future licensing deals** — Could create lumpy revenue recognition

- Clinical trial accruals affect the timing of R&D expense recognition
- CMC and nonclinical costs can fluctuate with development stage and vendor timing
- Fair value measurements can create non-cash volatility in other income/expense
- Derivative liabilities may materially affect reported earnings when remeasured
- Stock-based compensation is a meaningful operating expense for a small biotech
- Future collaboration or licensing revenue would depend on milestone and contract accounting
- Liquidity and going-concern assessments are important given recurring cash burn

---

*Last updated: 2026-08-11T04:46:21.774992+00:00*